Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
NVCR - NovoCure Limited
Market Cap 3.20B P/E - EPS this Y 31.30% Ern Qtrly Grth -
Income -168.7M Forward P/E -4.88 EPS next Y -5.20% 50D Avg Chg -37.00%
Sales 549.96M PEG -0.19 EPS past 5Y - 200D Avg Chg -56.00%
Dividend N/A Price/Book 7.72 EPS next 5Y 60.00% 52W High Chg -75.00%
Recommedations 2.40 Quick Ratio 6.20 Shares Outstanding 108.22M 52W Low Chg 1.00%
Insider Own 9.23% ROA -9.30% Shares Float 98.55M Beta 0.71
Inst Own 86.68% ROE -43.40% Shares Shorted/Prior 6.11M/6.48M Price 30.09
Gross Margin 75.96% Profit Margin -30.68% Avg. Volume 1,519,335 Target Price 27.17
Oper. Margin -22.35% Earnings Date Oct 30 Volume 1,276,382 Change -7.84%
Healthcare | Medical Devices | Jersey
About NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NovoCure Limited News
11:58 AM Novocure secures FDA approval for add-ons to brain cancer treatment wearable
07:05 AM Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
07:00 AM FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
10/31/24 NovoCure’s Strong Q3 and Leadership Changes in 2024
10/31/24 NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
10/30/24 NovoCure (NVCR) Q3 2024 Earnings Call Transcript
10/30/24 NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
10/30/24 NovoCure: Q3 Earnings Snapshot
10/30/24 Novocure Appoints Christoph Brackmann as Chief Financial Officer
10/30/24 Novocure Reports Third Quarter 2024 Financial Results
10/17/24 Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment
10/17/24 Novocure scoops FDA approval on wearable for metastatic cancer treatment
10/16/24 Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.
10/16/24 Novocure wins FDA approval for electric field device in lung cancer
10/16/24 FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
10/16/24 Novocure shares soar 33% as FDA approves lung cancer treatment
10/16/24 NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
10/15/24 FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
10/01/24 Novocure to Report Third Quarter 2024 Financial Results
09/09/24 Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
NVCR Chatroom

User Image Czm514 Posted - 2 hours ago

$NVCR Lifeless. News of new arrays sparks zero interest. Divine intervention needed to resurrect this dog. Very disappointing.

User Image TJmaximus Posted - 3 hours ago

$NVCR 2 fda approvals in the last 5 weeks and the stock is down, congrats to the team... keep up the good work

User Image TJmaximus Posted - 4 hours ago

$NVCR Look for a one time charge to switch out and phase in the new arrays.

User Image Stonkapedia Posted - 5 hours ago

$NVCR ooooh. Mouse data, straight outta Israel, rare super late stage brain cancer data, and new magical array data. Sounds juicy. 😂

User Image Tdorsey1776 Posted - 5 hours ago

$NVCR Improved arrays extend life and nice bottom line boost.

User Image TJmaximus Posted - 6 hours ago

$NVCR insiders get rich scheme

User Image TJmaximus Posted - 6 hours ago

$NVCR commercial TTF research institute

User Image Selett Posted - 7 hours ago

$NVCR new arrays approved.

User Image Scanners_Free Posted - 7 hours ago

$NVCR NEWS OUTTTTTTTT

User Image Stonkapedia Posted - 21 hours ago

$NVCR

User Image buylowandwait Posted - 22 hours ago

$NVCR Panova, Panova, where are thee EU approval, EU approval, where are thee Bill D, Bill D, I still can't grasp the meaning of thy words 2 weeks from now, I'll be leaving and watching thee on the side

User Image ZipRod Posted - 23 hours ago

$NVCR Electric Helmet Ponzi Scam!

User Image mohernx Posted - 1 day ago

$NVCR You are so right Guitar. Dancing baby and Chewie agree with you. Chew baby chew. 20 by year end!!!

User Image Guitar01 Posted - 2 days ago

$NVCR INSIDERS GOT RICH OFF THIS PONZI SCHEME SCAM COMPANY

User Image RealErnFranklin Posted - 4 days ago

$WLDS wearing it well. Perfect channel $RAPT boom $NVCR 5-5.50 range to buy and sell on repeat til it breaks $EBON china paying itself over and over on the market. Yes they rich rich from small caps $ZONE get urself some pay day. Monday social momo ticker. If blessed with a big green candle out the gate, thats your range to trade

User Image Ned_Nosurname Posted - 5 days ago

$NVCR https://www.cancernetwork.com/view/ttfields-plus-temozolomide-pembrolizumab-controls-tumors-in-glioblastoma

User Image GordonGecko_was_THE_MAN Posted - 5 days ago

$NVCR fun on a Friday after a poor week in the market: Anybody have a prediction for the Mike Tyson fight on Netflix tomorrow night?

User Image Tdorsey1776 Posted - 6 days ago

$NVCR https://www.tipranks.com/news/the-fly/novocure-participates-in-a-conference-call-with-jpmorgan

User Image Stonkapedia Posted - 6 days ago

$NVCR

User Image GordonGecko_was_THE_MAN Posted - 6 days ago

$NVCR Panova timing update: NVCR updated the clinicaltrials.gov site Oct 31: https://www.clinicaltrials.gov/study/NCT03377491 interesting notes: "last update submitted that met QC criteria" was on Oct 28, 2024. These updates must be complete before data lock and final analysis. assuming that was the last and final update, the data could not have been locked for more that 2 weeks at this point. not all that much time for analysis. Study is listed as complete as of Oct 16, 2024.

User Image NeuroRad Posted - 6 days ago

$NVCR I was planning to buy back in prior to panova TLD but I can’t bring myself to do it. The lack of any conviction from management, a lame duck ceo leaving on minimal notice for an unconvincing reason, and delay for data release relative to successful trials all factor in. Realistically, the odds of a panova success are low and the downside to the stock is immense given the lack of any expected revenue ramp until 2026 at the earliest from new indications. I am still holding my long term shares and I do have some leaps expiring in 2026, but I will not be adding any more. I still hold my thesis about an effective therapy without significant side effects. However, I can’t hold my account hostage if the company can’t translate that to prescriptions moving forward.

User Image ToRni27 Posted - 1 week ago

$NVCR is this good or is NVCR better? Its a first line lung cancer trial. Thank you for feedback! Median overall survival 32.9 months Median Progession free survival 12.7 months 24 months overall survival 81% of patients https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02880575-2A1562001

User Image Do_Your_Research Posted - 1 week ago

$NVCR I looked back at PANOVA2. The company recruited both locally advanced and metastatic patients for the phase 2 trial, then compared the results to the historical control from a trial that only treated metastatic patients. Really really shady of the company to do that. The results of the phase 2 trial might as well just be completely ignored. The phase 3 trial is going to compare locally advanced patients to locally advanced patients. They don’t get to manipulate the results like they did in phase 2. I pray that we see survival benefit similar to GBM, but I have absolutely no expectations for a home run.

User Image Chazdaq Posted - 1 week ago

$NVCR let’s make something happen!

User Image Tdorsey1776 Posted - 1 week ago

$NVCR

User Image oswan Posted - 1 week ago

$NVCR hit us with PANOVA results

User Image Stonkapedia Posted - 1 week ago

$NVCR

User Image 0DTE_trader Posted - 1 week ago

$NVCR bullish building value up in wick from last weekly candle. $18 has been a magnet level since the collapse Aug ‘23. Expect to chop around here at least thru options exp. LT sellers are drying up ✌🏽

User Image JuggernautRaider Posted - 1 week ago

$KPTI auditors are TERRIBLE at their jobs. There is a sushi restaurant that Richard has his leadership team use like a personal playground. They even have rolls named after Richard! Sell $KPTI Hold $BMY Byt $NVCR https://www.linkedin.com/posts/jeffrey-jay-conroy-80a39323_sushico-sushi-restaurant-in-newton-ma-activity

User Image Sensai0407 Posted - 1 week ago

$NVCR does anyone have TA on this? Why do I sense that this will squeeze…

Analyst Ratings
Evercore ISI Group In-Line Oct 1, 24
Wells Fargo Overweight Jul 26, 24
HC Wainwright & Co. Neutral Jul 26, 24
Evercore ISI Group In-Line Jul 2, 24
HC Wainwright & Co. Neutral Jun 4, 24
HC Wainwright & Co. Neutral May 2, 24
Piper Sandler Overweight Apr 10, 24
Wells Fargo Overweight Apr 3, 24
HC Wainwright & Co. Neutral Mar 27, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Shah Pritesh Chief Growth Officer Chief Growth Officer Nov 07 Sell 12.65 382 4,832 124,511 11/08/23
Weinberg Uri Chief Science Office.. Chief Science Officer Jan 05 Sell 117 8,143 952,731 43,286 01/09/23
Weinberg Uri Chief Science Office.. Chief Science Officer Jan 05 Option 47.04 1,946 91,540 49,050 01/09/23
Leonard Frank X President, CNS Cance.. President, CNS Cancers US Jan 05 Sell 113 39,507 4,464,291 46,158 01/09/23
Leonard Frank X President, CNS Cance.. President, CNS Cancers US Jan 05 Option 15.06 35,209 530,248 53,341 01/09/23
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Jan 05 Sell 108 387 41,796 82,843 01/09/23
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Jan 05 Sell 115.25 212,500 24,490,625 13,583 01/09/23
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Jan 05 Option 9.31 212,500 1,978,375 201,083 01/09/23
Leonard Frank X President, CNS Cance.. President, CNS Cancers US Sep 29 Sell 77.35 6,754 522,422 57,134 09/30/22
Leonard Frank X Chief Development Of.. Chief Development Officer Sep 09 Sell 88 1,863 163,944 84,150 09/12/22
Burke William Patrick Chief Human Resource.. Chief Human Resources Officer Sep 02 Sell 79.037 718 56,749 55,486 09/06/22
Cordova Ashley Chief Financial Offi.. Chief Financial Officer Sep 02 Sell 79.037 885 69,948 72,376 09/06/22
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Sep 02 Sell 79.037 296 23,395 165,024 09/06/22
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Sep 02 Sell 79.037 269 21,261 83,230 09/06/22
DOYLE WILLIAM F Executive Chairman Executive Chairman Aug 02 Sell 69.659 837 58,305 551,176 08/03/22
Benaim Ely Chief Medical Office.. Chief Medical Officer Aug 02 Sell 69.659 437 30,441 34,631 08/03/22
Leonard Frank X Chief Development Of.. Chief Development Officer Aug 02 Sell 69.659 414 28,839 102,193 08/03/22
Benaim Ely Chief Medical Office.. Chief Medical Officer May 10 Sell 63.2 4,205 265,756 34,846 05/12/22
Cordova Ashley Chief Financial Offi.. Chief Financial Officer Mar 03 Option 13.53 5,040 68,191 65,888 03/11/22
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Jul 31 Option 154.01 3,717 572,455 85,625 03/11/22
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Jul 31 Sell 71.19 3,669 261,196 83,187 03/11/22
Longsworth Todd Christopher General Counsel General Counsel Mar 03 Sell 72.45 3,067 222,204 64,801 03/07/22
Cordova Ashley Chief Financial Offi.. Chief Financial Officer Mar 03 Sell 72.45 1,705 123,527 61,607 03/07/22
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Mar 03 Sell 72.75 5,543 403,253 89,683 03/07/22
Benaim Ely Chief Medical Office.. Chief Medical Officer Mar 03 Sell 72.45 2,313 167,577 43,257 03/07/22
Burke William Patrick Chief Human Resource.. Chief Human Resources Officer Mar 03 Sell 72.45 1,367 99,039 57,028 03/07/22
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Mar 03 Sell 72.45 3,870 280,382 168,025 03/07/22
Leonard Frank X Chief Development Of.. Chief Development Officer Mar 03 Sell 72.45 1,485 107,588 103,039 03/07/22
DOYLE WILLIAM F Executive Chairman Executive Chairman Apr 15 Sell 203.1 95,000 19,294,500 555,393 04/15/21
LEUNG GABRIEL Director Director Apr 15 Option 31.45 6,000 188,700 78,045 04/15/21
LEUNG GABRIEL Director Director Apr 15 Sell 199.01 6,000 1,194,060 72,045 04/15/21
Benaim Ely Chief Medical Office.. Chief Medical Officer Apr 15 Option 66.74 5,958 397,637 36,733 04/15/21
Benaim Ely Chief Medical Office.. Chief Medical Officer Apr 15 Sell 200 5,958 1,191,600 33,259 04/15/21
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Mar 05 Sell 144.17 4,832 696,629 97,986 03/05/21
Cordova Ashley Chief Financial Offi.. Chief Financial Officer Mar 04 Sell 152.05 428 65,077 27,249 03/04/21
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Mar 04 Sell 152.05 912 138,670 91,932 03/04/21
Weinberg Uri Chief Science Office.. Chief Science Officer Feb 24 Option 7.15 6,500 46,475 34,097 02/24/21
Weinberg Uri Chief Science Office.. Chief Science Officer Feb 24 Sell 175.5 6,500 1,140,750 27,597 02/24/21
Benaim Ely Chief Medical Office.. Chief Medical Officer Dec 22 Option 65.43 2,484 162,528 30,007 12/22/20
Benaim Ely Chief Medical Office.. Chief Medical Officer Dec 22 Sell 156.71 2,484 389,268 29,356 12/22/20
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Dec 22 Option 22 207,910 4,574,020 301,587 12/22/20
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Dec 22 Sell 160.5 207,910 33,369,555 197,632 12/22/20
Weinberg Uri Chief Science Office.. Chief Science Officer Sep 28 Option 9.31 15,250 141,978 34,097 09/28/20
Weinberg Uri Chief Science Office.. Chief Science Officer Sep 28 Sell 103.35 15,250 1,576,088 27,597 09/28/20
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Sep 21 Option 7.48 8,262 61,800 150,869 09/21/20
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Sep 21 Sell 109.15 8,262 901,797 142,607 09/21/20
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Sep 18 Option 7.26 34,512 250,557 155,107 09/18/20
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Sep 18 Sell 107.78 34,512 3,719,703 142,607 09/18/20
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Sep 17 Option 22 103,000 2,266,000 300,632 09/17/20
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Sep 17 Sell 99 103,000 10,197,000 197,632 09/17/20